The global oncology company BeOne Medicines, formerly known as BeiGene, has redomiciled to Basel, Switzerland, to further support its continued global growth and set new standards in cancer care. The company has been present in Basel since 2018. Relocating to the Swiss city and adopting its new name, BeOne Medicines, are critical milestones in support of its mission to deliver innovative cancer treatments to more people around the world.  

“This move not only strengthens our operational presence in one of the world’s most dynamic biotech hubs, where more than 30,000 life sciences professionals work and live, but also enables closer collaboration with key scientific, regulatory and policy stakeholders across Europe”, says Giancarlo Benelli, Head of Region Europe at BeOne.  

“I am pleased that with BeOne Medicines, we have succeeded in attracting an innovative global oncology company to Basel. This relocation highlights the company’s strong commitment to the region and reinforces Basel’s status as one of Europe’s leading life science clusters,” says State Councilor Kaspar Sutter, Head of the Department of Economic, Social and Environmental Affairs. 

Commitment to innovation

BeOne pursues an integrated innovation strategy with in-house research, clinical development and manufacturing capabilities. The company has built a robust hematology pipeline – including a leading BTK inhibitor that is already approved in 75 countries. The company also develops new therapies for solid tumors such as breast, lung and gastrointestinal cancer based on modern platforms such as multispecific antibodies and protein degraders. 

Co-Founder, Chairman and CEO John V. Oyler emphasizes in a media release: “I am extremely proud of the progress we have made with our existing portfolio and our potentially transformative oncology pipeline of more than 50 investigational assets, the most prolific in the industry. After 15 years of relentless innovation and strategic investment to boost our internal global capabilities, we are just getting started, and I look forward to working together as BeOne.” 

In 2024 alone, BeOne brought 13 new drug candidates into clinical trials – a record figure even compared to the world’s largest pharmaceutical companies. Clinical activities extend across 45 countries; in Europe only, over 50 trials involving more than 4,000 patients are currently underway. With a growing global team of more than 11,000 employees spanning six continents, the Company is well-positioned to deliver global oncology treatments to patients worldwide.